France's Chauvin Invests At Aubenas

23 January 1995

French medium-sized drugmaker Laboratoire Chauvin, which specializes in ophthalmological drugs, is to reconstruct part of one of its production plants at Aubenas in the Ardeche area of the Rhone-Alpes region. The aim is to achieve Good Manufacturing Practice standards of sterile production.

The cost is estimated at 10 million French francs ($1.9 million). In addition, a unit to manufacture antihistamines and antiallergy products is to be established at a cost of some 1.7 million francs.

Laboratoire Chauvin, part of the Chauvin group, has two sites, one at Aubenas and one at Montpellier. It also has an export department in Paris. Sales in 1993 reached 342 million francs, with exports accounting for 24% of sales. The company is the leading producer of ophthalmological specialties in France, and is forecasting 1994 group sales of around 558 million francs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight